GSK generates £978m in Haleon stake sale

In a recent development, British pharmaceutical giant GSK has announced it successfully raised £978 million ($1.24 billion) through a strategic discounted stake sale in Haleon.

This move resulted in a reduction of GSK's ownership stake to 4.2pc in the independent consumer healthcare company globally.

The transaction involved the sale of approximately 300 million shares of its spun-off unit, with each share priced at 326 pence.

This financial maneuver underscores GSK's efforts to optimise its portfolio and allocate resources judiciously in the healthcare market.